Assembly Biosciences Inc

Assembly Biosciences maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The balance sheet holds $58.45 million in cash and equivalents against total assets of $257.59 million. Total liabilities stand at $50.84 million, while total equity is $206.75 million. The company reports a price-to-book ratio of 1.96 and an enterprise value-to-revenue multiple of 4.79. Operating cash flow is negative at -$41.09 million, reflecting ongoing investment in research and development typical of pre-profitability biotechnology firms. Capital expenditure is minimal at $66,000.

Profitability metrics indicate the company is not yet generating earnings, with a net income of -$6.12 million and an operating income of -$12.12 million. Return on equity is -2.96% and return on assets is -2.38%. The negative EV/EBITDA of -28.61 underscores the current lack of operating profit. Without cohort median data provided in the input, direct comparative analysis of profitability ratios against industry peers is omitted.

Revenue generation is limited to $72.30 million for the latest period. Specific segment and geographic revenue breakdowns are not provided in the available data, preventing analysis of revenue concentration or regional exposure.

Growth trajectory analysis is constrained by the absence of historical period data in the input. The current revenue figure of $72.30 million serves as the baseline for future performance evaluation.

Risk assessment indicates low liquidity risk and low dilution risk. No immediate filing-based liquidity or dilution flags were detected. The company has 15.86 million basic and diluted shares outstanding, with no immediate signs of share count expansion.

Recent observations include strong analyst sentiment, with a mean recommendation of 1.50 (strong buy) and a mean price target of $48.75. The high price target is $62.00, while the low is $40.00. There are two strong-buy ratings and two buy ratings, with no hold ratings. News events indicate system reconciliation activities but no specific corporate actions or clinical trial results were disclosed in the provided text.